Field Trip Health Ltd. is engaged in the development and delivery of psychedelic-assisted therapies (PAT). Through its Field Trip Discovery, the Company develops psychedelic molecules and conducts research on plant-based psychedelics. Field Trip Discovery focuses on developing medicines targeting the serotonin 5HT2A serotonin receptors. Its Field Trip Health division operates clinics across North America and Europe providing Ketamine-assisted psychotherapy (KAT) under various programs. Through its Field Trip Digital, it builds the digital and technological tools to support psychedelic experiences and consciousness expansion. The Company provides Trip and Portal applications. Its Trip is an iOS and Android application for consciousness expansion. Its Portal is a digital health platform for clients participating in psychedelic therapies at Field Trip Health centers.
No company officers listed.
No insider trading activity.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.